Belite Bio to Participate in the BTIG Ophthalmology Day
2023年11月20日 - 10:00PM
Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting degenerative retinal diseases that have significant unmet
medical needs, today announced that management will participate in
a fireside chat at the BTIG Ophthalmology Day on Monday,
November 27, 2023, at 3:00 p.m. ET.
The Belite management team will be participating in one-on-one
meetings at the event. Investors interested in meeting with Belite
at the conference should contact their BTIG representative.
About Belite Bio About Belite Bio Belite
Bio is a clinical-stage biopharmaceutical drug development company
focused on advancing novel therapeutics targeting degenerative
retinal diseases that have significant unmet medical needs, such as
Stargardt disease and geographic atrophy in advanced dry
age-related macular degeneration, in addition to specific metabolic
diseases. For more information, follow us
on Twitter, Instagram, LinkedIn, Facebook, or
visit us at www.belitebio.com.
Media and Investor Relations Contacts:
Jennifer Wuir@belitebio.com
Julie Fallon belite@argotpartners.com
Belite Bio (NASDAQ:BLTE)
過去 株価チャート
から 4 2024 まで 5 2024
Belite Bio (NASDAQ:BLTE)
過去 株価チャート
から 5 2023 まで 5 2024
